Valeant Pharmaceuticals

Pharmalot

Pharmalot, Pharmalittle: FTC is ‘aware’ of concerns over possible Mylan antitrust violations

By Ed Silverman

Valeant
Pharmalot

Feds charge former Valeant and Philidor execs with fraud

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant may change its name to create a new image

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Glaxo CEO looks for drug prices to fall no matter who is president

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant looks to sell Salix to lessen debt load

By Ed Silverman

Valeant
Pharmalot

Former Valeant CEO and CFO are being investigated by the feds

By Ed Silverman

Pharmalot

Congressman calls for probe into Valeant’s pricing of lead poisoning drug

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Drug makers are making huge bets on some cancer meds

By Ed Silverman

Valeant
Pharmalot

Huge Valeant price hike on lead poisoning drug sparks anger

By Ed Silverman

Medicine
Pharmalot

Rising drug prices are making hospitals feel ill

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Valeant
Pharmalot

Valeant avoids double-digit price hikes with 9.9 percent increases

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug

By Ed Silverman

Valeant Addyi
Pharmalot

Valeant gets poor grades for its Addyi female libido pill

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant under criminal investigation for defrauding insurers

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant reorganizes and maintains earnings forecast

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant overhauls part of its management team

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Valeant losing a crucial revenue tool

By Ed Silverman

Rising drug cost
The Pharmalot View

Pharma trade group says price gougers are outliers, but then accepts two more

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: FDA overlooks troubles at Chinese supplier to avoid shortages

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Novartis stops making TB drugs in Pakistan, prompting fear of a health crisis

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: FDA reviewers say Valeant drug carries suicide risks

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Medivation to start takeover talks with Sanofi and others

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: India inspects 200 drug makers for poor-quality meds

By Ed Silverman

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy